Details for Patent: 11,298,356
✉ Email this page to a colleague
Which drugs does patent 11,298,356 protect, and when does it expire?
Patent 11,298,356 protects PHYRAGO and is included in one NDA.
This patent has six patent family members in six countries.
Drugs Protected by US Patent 11,298,356
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanocopoeia | PHYRAGO | dasatinib | TABLET;ORAL | 216099-001 | Dec 5, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Nanocopoeia | PHYRAGO | dasatinib | TABLET;ORAL | 216099-002 | Dec 5, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Nanocopoeia | PHYRAGO | dasatinib | TABLET;ORAL | 216099-003 | Dec 5, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Nanocopoeia | PHYRAGO | dasatinib | TABLET;ORAL | 216099-004 | Dec 5, 2023 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,298,356
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2021210974 | ⤷ Subscribe | |||
| Canada | 3168667 | ⤷ Subscribe | |||
| European Patent Office | 4093379 | ⤷ Subscribe | |||
| Israel | 294928 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
